Blog‎ > ‎

Will CXL Finally Get Approved?

posted Oct 23, 2015, 9:51 AM by Jen Weigel
From Avedro:

"Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company is pleased to announce that it has resubmitted its New Drug Application (NDA) for riboflavin ophthalmic solution/KXL®System to the U.S. Food and Drug Administration (FDA), which is a key milestone in the drug approval process. Avedro anticipates an application action date (PDUFA) in April 2016.  If approved, the NDA would be the first FDA approved therapeutic treatment for progressive keratoconus and corneal ectasia following refractive surgery."

To see the full press release, click here.